Conditions: Opioid Related Disorders Opioid Dependence Opioid Addiction
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 106
Healthy volunteers: no

Brief summary:
This is a study of tramadol as an agent for short-term opioid withdrawal treatment. A randomized, double blind clinical trial comparing the efficacy and safety of tramadol to clonidine and buprenorphine in the short-term treatment of opioid withdrawal will be conducted. Opioid dependent participants will be treated on a residential unit. The primary outcome measure is opioid withdrawal symptoms.

Detailed description:

Arms:
arm 1: Sublingual buprenorphine/naloxone tablets (or placebo) arm 2: Oral clonidine tablets (or placebo) arm 3: Oral tramadol tablets (or placebo)

Interventions: intervention 1: Buprenorphine/naloxone intervention 2: Clonidine intervention 3: Tramadol ER
Intervention descriptions: intervention 1: up to 8/2 mg Sublingual (SL) per day intervention 2: up to 0.8 mg per day (oral) intervention 3: up to 600 mg per day

Protocol document: